NO20074443L - Fremgangsmate for svak fordelingskromatografi - Google Patents

Fremgangsmate for svak fordelingskromatografi

Info

Publication number
NO20074443L
NO20074443L NO20074443A NO20074443A NO20074443L NO 20074443 L NO20074443 L NO 20074443L NO 20074443 A NO20074443 A NO 20074443A NO 20074443 A NO20074443 A NO 20074443A NO 20074443 L NO20074443 L NO 20074443L
Authority
NO
Norway
Prior art keywords
procedure
distribution chromatography
weak distribution
weak
chromatography
Prior art date
Application number
NO20074443A
Other languages
English (en)
Norwegian (no)
Inventor
Brian Kelley
Shujun Sun
Paul Brown
Jon Coffman
Ranganathan Godvarti
Tim Iskra
Suresh Vunnum
Tianning Yu
James Edward Booth
Mary Beth Switzer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074443(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074443L publication Critical patent/NO20074443L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30Partition chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32Bonded phase chromatography
    • B01D15/325Reversed phase
    • B01D15/327Reversed phase with hydrophobic interaction
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361Ion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3828Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NO20074443A 2005-03-11 2007-09-03 Fremgangsmate for svak fordelingskromatografi NO20074443L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66043705P 2005-03-11 2005-03-11
PCT/US2006/008919 WO2006099308A2 (en) 2005-03-11 2006-03-10 A method of weak partitioning chromatography

Publications (1)

Publication Number Publication Date
NO20074443L true NO20074443L (no) 2007-09-27

Family

ID=36992346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074443A NO20074443L (no) 2005-03-11 2007-09-03 Fremgangsmate for svak fordelingskromatografi

Country Status (21)

Country Link
US (3) US8067182B2 (zh)
EP (1) EP1869065B1 (zh)
JP (1) JP5199063B2 (zh)
KR (2) KR101660575B1 (zh)
CN (2) CN104610422A (zh)
AU (1) AU2006223180B2 (zh)
BR (1) BRPI0608584B8 (zh)
CA (1) CA2601062C (zh)
CR (1) CR9377A (zh)
DK (1) DK1869065T3 (zh)
ES (1) ES2797480T3 (zh)
HK (1) HK1210476A1 (zh)
HU (1) HUE049797T2 (zh)
IL (1) IL185687A (zh)
MX (1) MX2007011129A (zh)
NO (1) NO20074443L (zh)
PL (1) PL1869065T3 (zh)
PT (1) PT1869065T (zh)
RU (1) RU2457214C2 (zh)
SI (1) SI1869065T1 (zh)
WO (1) WO2006099308A2 (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5199063B2 (ja) * 2005-03-11 2013-05-15 ワイス・エルエルシー 弱分配クロマトグラフィー方法
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
PL2061803T5 (pl) 2006-08-28 2023-03-27 Ares Trading S.A. Proces oczyszczania białek zawierających fc
KR20090064377A (ko) * 2006-09-08 2009-06-18 와이어쓰 친화성 크로마토그래피를 사용하는 단백질 정제에 있어서 아르기닌 세척
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
RU2520810C2 (ru) * 2006-11-08 2014-06-27 Вайет Рационально разработанные среды для культивирования клеток
EP3441402A1 (en) * 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009092014A1 (en) * 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
FI3604324T3 (fi) 2008-08-14 2024-05-16 Genentech Inc Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa
WO2010030222A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
US20100069617A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
CA2932207A1 (en) * 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
BRPI0919979A2 (pt) 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US9631008B2 (en) * 2008-12-22 2017-04-25 Hoffmann-La Roche Inc. Immunoglobulin purification
SG181771A1 (en) * 2009-12-18 2012-07-30 Novartis Ag Wash solution and method for affinity chromatography
CA2787009C (en) 2010-01-15 2018-04-03 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
EP2575847B2 (en) * 2010-05-25 2022-04-27 F. Hoffmann-La Roche AG Methods of purifying polypeptides
EP2583973B1 (en) * 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US9428546B2 (en) 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
WO2012068134A1 (en) 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
US9592540B2 (en) 2011-02-02 2017-03-14 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US10221210B2 (en) 2011-07-20 2019-03-05 Zepteon, Incorporated Polypeptide separation methods
DK3257564T4 (da) 2011-11-02 2024-09-02 Hoffmann La Roche Overstrøms- og elutionskromatografi
SG10201701224UA (en) 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
CN104507955A (zh) * 2012-05-31 2015-04-08 新加坡科技研究局 采用具有多形式官能性的颗粒对免疫球蛋白g制备物的色谱纯化
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN104837536B (zh) 2012-12-14 2018-01-02 通用电气医疗集团生物工艺研发股份公司 清洁填充床层析柱的方法
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095615A1 (es) * 2013-03-15 2015-10-28 Alder Biopharmaceuticals Inc Purificación de anticuerpos y monitoreo de pureza
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR101891522B1 (ko) 2013-12-12 2018-08-24 이엠디 밀리포어 코포레이션 아크릴아미드 함유 필터를 사용한 단백질 분리
US10099157B2 (en) 2014-06-23 2018-10-16 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
EP3157689B1 (en) 2014-06-23 2021-04-28 Bio-Rad Laboratories, Inc. Apatite pretreatment
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
WO2019224660A1 (ja) * 2018-05-24 2019-11-28 HOYA Technosurgical株式会社 吸着剤の生産方法
WO2020023566A1 (en) * 2018-07-25 2020-01-30 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
CN115023276A (zh) * 2020-01-29 2022-09-06 默沙东有限公司 从抗-lag3抗体生产中分离宿主细胞脂肪酶的方法
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
AU2022332274A1 (en) 2021-08-23 2024-02-15 Genentech, Inc. Flow through cation exchange chromatography purification processes for antibody drug conjugates
WO2024145232A1 (en) * 2022-12-30 2024-07-04 Eli Lilly And Company Methods of dulaglutide purification using hydrophobic interaction chromatography

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029583A (en) * 1975-02-28 1977-06-14 Purdue Research Foundation Chromatographic supports and methods and apparatus for preparing the same
JPS63126826A (ja) 1986-11-14 1988-05-30 Asahi Chem Ind Co Ltd プラスミノ−ゲン活性化因子誘導物質
KR930008447B1 (ko) * 1987-10-23 1993-09-04 쉐링 코포레이션 단백질 정제방법
US5451662A (en) 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US4983722A (en) 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
ES2064412T3 (es) 1988-10-26 1995-02-01 American Cyanamid Co Procedimiento para reducir el contenido de aglomerado de materiales tipo hormona del crecimiento.
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
FR2703049B1 (fr) 1993-03-22 1995-04-21 Rhone Poulenc Rorer Sa Procédé de purification des taxoïdes.
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1995026977A1 (en) * 1994-04-01 1995-10-12 Unisyn Technologies, Inc. High salt binding buffer for immunoglobulin purification with a synthetic affinity ligand
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
RU2094077C1 (ru) * 1996-07-23 1997-10-27 Акционерное общество закрытого типа "Фосфосорб" Хроматографический способ выделения альфа-фетопротеина
TW505655B (en) 1997-10-14 2002-10-11 Tanox Inc Enhanced aggregate removal from bulk-biologicals using ion exchange chromatography
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
AU6254799A (en) 1998-09-16 2000-04-03 Tanox, Inc. Anti-ige gene therapy
AU777203B2 (en) 1998-12-30 2004-10-07 Hans Olof Johansson Separation method utilizing liquid-liquid partition
AU2002359816B2 (en) 2001-12-21 2006-07-13 Immunex Corporation Methods for purifying protein
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
WO2004076485A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
JP4496168B2 (ja) * 2003-07-28 2010-07-07 株式会社リバース・プロテオミクス研究所 非特異的物質の除去方法
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
CA2543193C (en) * 2003-10-27 2015-08-11 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
JP5199063B2 (ja) 2005-03-11 2013-05-15 ワイス・エルエルシー 弱分配クロマトグラフィー方法

Also Published As

Publication number Publication date
CN104610422A (zh) 2015-05-13
RU2007132851A (ru) 2009-04-20
IL185687A0 (en) 2008-01-06
KR101660575B1 (ko) 2016-09-27
HUE049797T2 (hu) 2020-10-28
DK1869065T3 (da) 2020-06-08
CR9377A (es) 2008-02-21
AU2006223180B2 (en) 2011-11-24
PT1869065T (pt) 2020-06-18
ES2797480T3 (es) 2020-12-02
SI1869065T1 (sl) 2020-08-31
CN101175765A (zh) 2008-05-07
BRPI0608584B8 (pt) 2021-05-25
AU2006223180A1 (en) 2006-09-21
RU2457214C2 (ru) 2012-07-27
HK1210476A1 (zh) 2016-04-22
JP5199063B2 (ja) 2013-05-15
KR20070121667A (ko) 2007-12-27
CA2601062A1 (en) 2006-09-21
US8067182B2 (en) 2011-11-29
KR101482791B1 (ko) 2015-01-21
IL185687A (en) 2015-05-31
JP2008533473A (ja) 2008-08-21
PL1869065T3 (pl) 2020-09-21
EP1869065A4 (en) 2012-07-04
WO2006099308A2 (en) 2006-09-21
MX2007011129A (es) 2007-11-06
BRPI0608584B1 (pt) 2018-02-06
CA2601062C (en) 2016-08-02
WO2006099308A3 (en) 2007-10-25
EP1869065B1 (en) 2020-05-06
US9144755B2 (en) 2015-09-29
KR20130128020A (ko) 2013-11-25
US20070060741A1 (en) 2007-03-15
US20120138537A1 (en) 2012-06-07
US20070054390A1 (en) 2007-03-08
BRPI0608584A2 (pt) 2010-01-19
EP1869065A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20074443L (no) Fremgangsmate for svak fordelingskromatografi
WO2008036168A3 (en) New small molecule inhibitors of mdm2 and the uses thereof
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
AR064456A1 (es) Anticuerpos cd 44
MX2007010272A (es) Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
CL2008003866A1 (es) Compuestos derivados de azolilmetiloxirano; composicion que los contienen; procedimiento para combatir hongos fitopatogenos; procedimiento para la obtencion de antimicotico; semilla.
WO2007085895A3 (en) Fap inhibitors
CL2008001896A1 (es) 3-dihalometil-1-metil-1h-pirazol-4-carbaldehidos; su proceso de preparacion usando un intermediario de hidrazona, que reacciona con un agente de vilsmeier; y el derivado de hidrazona usado.
DK1968372T3 (da) Promotorsekvens opnået fra ris samt anvendelsesfremgangsmåder
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
NO20071901L (no) Substituerte bisykliske imidazo-3-ylamin sammensetninger
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
WO2010027975A8 (en) Boron-containing small molecules
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
SG144809A1 (en) Benzimidazole compounds and their use as chromatographic ligands
WO2009002380A3 (en) Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
TW200740814A (en) Compounds
WO2006103253A3 (de) Bohrspülung enthaltend hydrophobin
WO2008097342A3 (en) Compositions and methods for isolation of biological molecules

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application